Literature DB >> 2870131

Brain dopamine D-2 receptors in senile dementia.

J O Rinne, E Säkö, L Paljärvi, P K Mölsä, U K Rinne.   

Abstract

Brain dopamine D-2 receptors were analysed in the caudate nucleus, putamen and nucleus accumbens in 49 patients with different types of neuropathologically verified dementia and in 39 controls by the binding of 3H-spiroperidol. The binding was significantly decreased in all brain areas in patients with Alzheimer's disease (AD), while the changes in patients with multi-infarct dementia (MID) or combined dementia (CD) were non-significant. According to a Scatchard analysis, this decrease in binding was due to the reduced number of receptors. On the other hand, the binding of 3H-spiroperidol was significantly increased in those patients who had received neuroleptic drugs. Significant correlations between 3H-spiroperidol binding and neuropathological changes were seen only in AD patients in the nucleus accumbens. The nucleus accumbens was also the only brain area in which there was a significant correlation between dopamine D-2 and the number of muscarinic receptors in AD patients. The findings of this study on dopamine D-2 receptors suggest the involvement of the nigrostriatal dopaminergic system in AD but not in the other two major types of dementia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2870131     DOI: 10.1007/bf01249611

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  29 in total

1.  Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.

Authors:  J D Parkes; C D Marsden; J E Rees; G Curzon; B D Kantamaneni; R Knill-Jones; A Akbar; S Das; M Kataria
Journal:  Q J Med       Date:  1974-01

Review 2.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

3.  Further evidence for the involvement of D2, but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission.

Authors:  B Scatton
Journal:  Life Sci       Date:  1982-12-20       Impact factor: 5.037

4.  Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: analysis and examples.

Authors:  P Seeman; C Ulpian; K A Wreggett; J W Wells
Journal:  J Neurochem       Date:  1984-07       Impact factor: 5.372

5.  Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains.

Authors:  T Lee; P Seeman; W W Tourtellotte; I J Farley; O Hornykeiwicz
Journal:  Nature       Date:  1978-08-31       Impact factor: 49.962

6.  Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences.

Authors:  P Riederer; K Jellinger
Journal:  Exp Brain Res       Date:  1982       Impact factor: 1.972

7.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

Authors:  D M Bowen; C B Smith; P White; A N Davison
Journal:  Brain       Date:  1976-09       Impact factor: 13.501

8.  Dopamine receptors in the Parkinsonian brain.

Authors:  U K Rinne; P Lönnberg; V Koskinen
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

9.  Increased brain dopamine and dopamine receptors in schizophrenia.

Authors:  A V Mackay; L L Iversen; M Rossor; E Spokes; E Bird; A Arregui; I Creese; S H Synder
Journal:  Arch Gen Psychiatry       Date:  1982-09

10.  Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome.

Authors:  C M Yates; J Simpson; A Gordon; A F Maloney; Y Allison; I M Ritchie; A Urquhart
Journal:  Brain Res       Date:  1983-11-28       Impact factor: 3.252

View more
  5 in total

Review 1.  Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.

Authors:  Riqiang Yan; Qingyuan Fan; John Zhou; Robert Vassar
Journal:  Neurosci Biobehav Rev       Date:  2016-04-01       Impact factor: 8.989

Review 2.  Monoamine neurons in aging and Alzheimer's disease.

Authors:  A M Palmer; S T DeKosky
Journal:  J Neural Transm Gen Sect       Date:  1993

3.  Pharmacokinetics and dopamine/acetylcholine releasing effects of ginsenoside Re in hippocampus and mPFC of freely moving rats.

Authors:  Jing Shi; Wei Xue; Wen-jie Zhao; Ke-xin Li
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

4.  Dopaminergic dysfunction in the 3xTg-AD mice model of Alzheimer's disease.

Authors:  Yesica Gloria; Kelly Ceyzériat; Stergios Tsartsalis; Philippe Millet; Benjamin B Tournier
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

Review 5.  "Is dopamine involved in Alzheimer's disease?".

Authors:  Alessandro Martorana; Giacomo Koch
Journal:  Front Aging Neurosci       Date:  2014-09-25       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.